ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1507	National Cancer Institute	Html	en	Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of extragonadal germ cell tumors.	residual mass 0.384023 large tumor volume 0.30085 residual disease. 0.273583 recurrent testicular cancer. 0.3175 cisplatin-based chemotherapy regimens 0.371374 PDQ cancer information 0.391809 bulky tumors 0.328858 nonseminoma germ cell 0.421124 cell tumors. 0.272309 nonseminomatous germ cell 0.40313 clinical trials 0.311324 relatively small tumors 0.373793 germ cells 0.335003 particularly young individuals 0.307507 Initial chemotherapy 0.290755 cancer information summary 0.37005 breast cancer prevention 0.298248 careful testicular examination 0.334354 Initial debulking surgery 0.299396 extragonadal primary tumors 0.367991 patients 0.377174 BEP regimen 0.273424 NCI’s PDQ 0.288373 PDQ Adult Treatment 0.321273	NCI PDQ cancer 0.337916 Craniospinal radiation therapy 0.306681 extragonadal germ cell 0.679693 international germ cell 0.403901 tumor prognostic classification 0.317369 overall survival rates 0.302813 long-term disease-free survival 0.296962 chemotherapy course 0.295979 major clinical trial 0.309884 autologous bone marrow 0.294582 advanced disseminated germ 0.372421 seminomatous germ cell 0.403127 nonseminomatous extragonadal germ 0.370944 testicular seminoma 0.333059 serum alpha fetoprotein 0.309001 high-risk patients 0.281542 larger residual masses 0.321492 National Cancer Institute 0.298826 PDQ documents 0.279503 nonseminoma testicular cancer 0.332786 nonlocalized tumors 0.326576 germ cell tumors 0.92252 residual mass posttreatment 0.32699 Hematologic toxic effects 0.298226	CLICK HERE
1666	National Cancer Institute	Html	en	Testicular Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for testicular cancer.	testicular self-exams 0.545422 ongoing clinical trials 0.499986 PDQ cancer information 0.758311 testicular cancer 0.955987 testicular germ cell 0.59857 testicular carcinoma 0.546926 NCI Web site 0.507088 testicular cancers 0.553122 clinical trials 0.669739 early detection 0.495849 germ cells 0.505641 cancer information summary 0.64569 clinical trial 0.511819 breast cancer prevention 0.524202 spermatic cord 0.49407 PDQ summaries 0.534816 cancer patients 0.49191 latest published information 0.509374 NCI’s PDQ 0.538459 cancer symptoms 0.51215 NCI PDQ cancer 0.620022 tests 0.527688 testicular cancer screening 0.701295 routine screening test 0.519043	PDQ Screening 0.553678 testicles 0.486139 screening tests 0.48752 Cancer Information Service 0.545478 common cancer 0.501504 male sex glands 0.496865 Prevention Editorial Board 0.56412 treatment clinical trials 0.501604 National Cancer Institute 0.653794 PDQ documents 0.525451 cancer doctors 0.485997 long coiled tube 0.493438 new treatment 0.506259 health professional version 0.485461 Cancer screening trials 0.571582 PDQ database 0.532773 Cancer Care page 0.527585 Testicular Cancer Treatment 0.685082 risk factor 0.499445 PDQ summary 0.654344 routine physical exam 0.576949 cancer information summaries 0.554625 health professional versions 0.489301 comprehensive cancer information 0.555761	CLICK HERE
1716	National Cancer Institute	Html	en	Human Papillomavirus (HPV) Vaccines	A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer.	transmitted HPV types 0.372301 HPV prophylactic vaccines 0.352103 anal HPV 0.291899 HPV transmission 0.315597 available HPV vaccine 0.365066 HPV types 0.787213 Disease Control 0.208664 HPV vaccination coverage 0.329587 HPV vaccination program 0.333099 bivalent HPV vaccination 0.335395 hpv vaccination 0.566558 cervical cancer 0.335142 high-risk HPV infections 0.38085 HPV surface components 0.326712 genital HPV infection 0.36709 available HPV vaccines 0.389305 persistent HPV 0.314117 high-risk hpv types 0.523029 HPV vaccines 0.696012 human papillomavirus 0.38319 HPV vaccination series 0.361602 HPV infections 0.517426 genital HPV infections 0.379278 contact.  HPV infections 0.352636 human papillomavirus vaccine 0.256852	hpv infection 0.466234 current HPV vaccines 0.379891 women 0.226009 United States 0.375279 Updated HPV Vaccination 0.330423 current HPV infections 0.328908 therapeutic HPV vaccines 0.356162 human papillomavirus vaccines 0.212379 HPV Vaccination Recommendations 0.367966 Yes. Because HPV 0.297056 dozen high-risk HPV 0.362742 HPV 0.924148 routine HPV vaccination 0.357555 genital warts 0.26905 quadrivalent HPV vaccine 0.329163 additional HPV types 0.3896 quadrivalent human papillomavirus 0.21339 HPV vaccine product 0.372857 additional high-risk HPV 0.343778 currently approved HPV 0.315107 high-risk HPV type 0.392493 Gardasil 0.309437 vaccine-targeted HPV types 0.33361 et al 0.409031	CLICK HERE
1804	National Cancer Institute	Html	es	Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama).	Surgical Adjuvant Breast 0.311283 node-positive breast 0.305691 susceptibility to breast 0.306299 results from 0.304936 node-negative breast carcinoma 0.307067 linfáticos internos mamarios 0.304657 invasive breast 0.310223 MammaPrint breast 0.305772 metástasis manifiesta 0.303936 Breast Cancer Family 0.311467 invasive breast carcinoma 0.30652 breast magnetic resonance 0.305716 Breast Cancer Linkage 0.318171 with node-negative breast 0.307174 brca2 mutation 0.31001 early breast 0.305558 Metástasis ipsilateral rodaderab 0.30419 Cancer Linkage Consortium 0.309543 risk factors 0.310931 ganglio centinela 0.304343 mucinous breast carcinomas 0.305818 Natl Cancer Inst 0.352497 breast carcinomas 0.328163 Women's Health Initiative 0.304548 node-negative breast 0.315228	N2b Metástasis 0.303847 from benign breast 0.306434 N2a Metástasis 0.30385 BRCA2 mutation carriers 0.309625 investigation into cancer 0.309168 Bilateral breast carcinoma 0.306729 ganglios positivos.Se 0.305633 Lancet Oncol 0.305043 contralateral breast 0.320411 lobular breast 0.305977 benign breast 0.312903 ganglio linfático centinela 0.333143 ganglios satélites 0.30541 Cancer Staging Manual 0.308858 Cancer Res Treat 0.315484 Clin Oncol 0.389208 breast carcinomas distinguish 0.305804 breast cancer 0.999811 Relat Cancer 0.305724 BRCA2-associated breast 0.305731 with invasive breast 0.307222 family history 0.30714 AJCC Cancer Staging 0.309184 Breast Cancer Res 0.348498	CLICK HERE
1858	National Cancer Institute	Html	es	Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales.	salivary gland carcinoma 0.756611 salivary neoplasms 0.424559 estroma linfoide 0.413137 prognostic factors 0.41902 gland tumours 0.43032 Spiro RH 0.465562 Sin embargo 0.429856 advanced salivary 0.421758 Malignant parotid tumors 0.41189 minor salivary 0.423431 tumores benignos 0.597781 Salivary Gland Disease 0.423228 tumores malignos mixtos 0.484605 botulinum toxin 0.428989 Radiat Oncol Biol 0.471433 glándulas salivales benignos 0.570833 neck neoplasia following 0.437258 fuerte predilección 0.414088 Parotid gland tumours 0.420714 salivary gland 0.859636 Head Neck Surg 0.476609 mucoepidermoid carcinoma 0.597885 gland malignant neoplasms 0.445484 tumores benignos mixtos 0.438326 único síntoma 0.425265	parotid gland 0.431427 lesiones carcinoma 0.466113 relativa frecuencia 0.450675 sección carcinoma 0.486375 carcinoma ex-tumor 0.470245 unresectable carcinomas 0.426636 Oral Oncol 0.420027 major salivary glands 0.414421 Otolaryngol Head Neck 0.413034 término carcinoma 0.475993 carcinoma epidermoide 0.472012 edad promedio 0.670934 Salivary Gland Tumours 0.424182 carcinoma with 0.481329 adenocarcinoma sai 0.463524 carcinoma salival basaloide 0.481935 carcinomas quísticos adenoides 0.459095 Botulinum toxin treatment 0.413697 with parotid carcinoma 0.483397 Oncol Biol Phys 0.47266 linfadenoma sebáceo 0.417003 elemento carcinoma 0.475416 carcinoma mucoepidermoide 0.988653 neoplasias benignas 0.45166	CLICK HERE
4300	National Cancer Institute	Html	en	Cancer Moonshot℠ Blue Ribbon Panel	The Blue Ribbon Panel Report outlines 10 recommendations to accelerate progress against cancer. The panel was established to ensure that the Cancer Moonshot's approaches are grounded in the best science.	BRP 0.544911 National Cancer Advisory 0.917882 pediatric cancer 0.537601 relevant scientific sectors 0.512578 Reduce cancer risk 0.54942 dynamic 3D maps 0.479491 early detection 0.494934 therapeutic targets 0.493364 presidentially appointed National 0.528792 new preclinical models 0.493659 national cancer data 0.584851 previously effective treatments 0.485016 early detection strategies 0.482919 new therapeutic targets 0.480719 cancer resistance 0.471789 E. Intensify research 0.49241 translational science network 0.495254 cancer technologies 0.513048 public idea submission 0.473834 broader cancer community 0.579774 transformative research recommendations 0.554836 cancer immunotherapy network 0.593107 Ribbon Panel report 0.661804 tumor evolution 0.579883	cancer health disparities 0.557334 final recommendations 0.465114 Cancer Immunology 0.464811 human tumor evolution 0.504864 specific recommendations 0.466439 cancer prevention 0.548373 C. Develop ways 0.499508 tumor profile data 0.530939 cancer cells 0.472187 group members 0.429792 Minimize cancer treatment 0.561924 direct patient involvement 0.494413 joint recommendations 0.465939 3D cancer atlas 0.546232 multiple groups 0.44011 Cancer Moonshot Task 0.60025 Blue Ribbon Panel 0.890429 groups 0.493987 BRP members 0.537843 major topic areas 0.508582 Cancer Advisory Board 0.925259 efficient data analysis 0.49446 Develop new cancer 0.562862 future patient outcomes 0.484191	CLICK HERE
15908	National Cancer Institute	Html	es	Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer.	Natl Acad Sci 0.351583 institute's retrospective laetrile 0.328712 treated with laetrile 0.349302 Exp Med Surg 0.328157 Promoting poison 0.33939 antitumor activity 0.465434 cases treated with 0.28668 treatment with laetrile 0.295229 with laetrile 0.90547 CA Cancer 0.770829 Acta Unio Int 0.423146 Cancer Industry 0.474642 Med Hypotheses 0.298922 Cancer Commission 0.379224 Estados Unidos 0.752083 Amygdalin induces apoptosis 0.284053 Navarro MD 0.430756 Unio Int Contr 0.427919 Five years 0.324596 Ellison NM 0.316229 Bickis IJ 0.282987 Acad Med 0.304051 Ames MM 0.502122 Laetrile toxicity studies 0.333014 Med Assoc 0.356472	Diss Abstr Int 0.346583 years experience with 0.456942 Proc Natl Acad 0.355643 vía oral 0.317497 Laetrile toxicity 0.342269 retrospective laetrile analysis 0.331541 Cancer Establishment 0.478533 experience with laetrile 0.549066 Dorr RT 0.337868 Cancer Institute retrospective 0.411789 Unproven methods 0.542254 Treat Rep 0.798281 current status 0.343299 Intern Med 0.566133 Kovach JS 0.535271 with laetrile therapy 0.559394 Clin Nutr 0.378962 Int Contr Cancrum 0.427916 laetrile intoxication 0.281414 Moertel CG 0.440121 Herbert V 0.324024 NCI Laetrile Review 0.334924 Paxinos J 0.340814 Med Chem 0.296011	CLICK HERE
16839	National Cancer Institute	Html	en	Previous NCI Alliance Grantees	The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects.	cancer-related nanotechnology research 0.909204 initiative 0.300481 private organizations 0.515908 Focus 0.261214 National Cancer Institute 0.829641	clinical practice 0.510503 clinicians 0.293138 areas 0.260532 NCI Alliance 0.657758 major commitment 0.597371	CLICK HERE
16853	National Cancer Institute	Html	es	Toxicidad financiera del tratamiento del cáncer (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del riesgo de sufrir dificultades financieras durante el tratamiento del cáncer.	Medicare Part 0.308522 seguros médicos 0.305373 siguientes factores 0.311301 Physician Data Query 0.329894 peores efectos 0.307687 Mala salud 0.316385 Estados Unidos 0.307928 siguientes tipos 0.309519 siguientes situaciones 0.309327 toxicidad financiera quizás 0.339997	PDQ Toxicidad 0.324969 menor gasto 0.305929 profesionales médicos 0.305255 deducible alto 0.308691 seguro complementario 0.312367 National Cancer Institute 0.30786 siguientes riesgos 0.306049 seguro médico 0.99746 Instituto Nacional 0.313756 determinados tipos 0.308082	CLICK HERE
17294	National Cancer Institute	Html	es	Anemia	Información y consejos para controlar la anemia, un efecto secundario del tratamiento del cáncer.	suficientes glóbulos 0.941582		CLICK HERE